Evidence map›Paper›PMID 40643845›Full record

ArticleAdvances in therapy2025

Correction to: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.

Peter C Taylor, Thomas Bieber, Rieke Alten, Torsten Witte, James Galloway, Walter Deberdt, Maher Issa, Ewa Haladyj, Inmaculada De La Torre, Susanne Grond and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Peter C TaylorThe Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. peter.taylor@kennedy.ox.ac.uk.ORCID http://orcid.org/0000-0001-7766-6167
Thomas BieberDepartment of Dermatology and Allergy, University of Bonn, Bonn, Germany.
Rieke AltenDepartment of Internal Medicine and Rheumatology, Schlosspark-Klinik Charité, University Medicine Berlin, Berlin, Germany.
Torsten WitteClinical Immunology, Hannover Medical School, Hannover, Germany.
James GallowayCentre for Rheumatic Diseases, King's College London, London, UK.
Walter DeberdtEli Lilly and Company, Indianapolis, IN, USA.
Maher IssaEli Lilly and Company, Indianapolis, IN, USA.
Ewa HaladyjEli Lilly and Company, Indianapolis, IN, USA.
Inmaculada De La TorreEli Lilly and Company, Indianapolis, IN, USA.
Susanne GrondEli Lilly and Company, Indianapolis, IN, USA.
Andreas WollenbergDepartment of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40643845
PMCPMC12394327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.